Combination chemotherapy of S-1 plus biweekly docetaxel for advanced and recurrent gastric cancer

Ikuo Takahashi, Eiji Oki, Akinori Egashira, Masaru Morita, Yoshihiro Kakeji, Yoshihiko Maehara

Research output: Contribution to journalReview article

Abstract

The S-1 +biweekly docetaxel (DOC) combination therapy was evaluated for advanced or recurrent gastric cancer patients. This combination therapy was evaluated in vitro using the nude rat-gastric cancer xenograft system. S-1 alone or DOC alone showed antitumor activity, and the antitumor activity was synergistic when two drugs were combined. In clinical settings, the schedule was S-1 80 mg/m2 (day 1-14, orally) and DOC (day 1 and day 15, intravenously) followed by a 2-week rest. In phase I study, the dose of DOC was evaluated, and a recommended dose for phase II was determined as 35 mg/m2. The entry for phase II study was completed, and the preliminary results of 33 patients showed the response rate of 21.2%. The incidence of more than grade 3 adverse effects was 29%(neutropenia, leukocytopenia, anorexia and mucositis). The S-1 +biweekly DOC combination therapy can be a candidate for outpatient chemotherapy for advanced or recurrent gastric cancer.

Original languageEnglish
Pages (from-to)87-90
Number of pages4
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume33 Suppl 1
Publication statusPublished - Jan 1 2006

Fingerprint

docetaxel
Combination Drug Therapy
Stomach Neoplasms
Nude Rats
Mucositis
Leukopenia
Anorexia
Neutropenia
Heterografts
Appointments and Schedules
Outpatients
Therapeutics
Drug Therapy
Incidence

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Combination chemotherapy of S-1 plus biweekly docetaxel for advanced and recurrent gastric cancer. / Takahashi, Ikuo; Oki, Eiji; Egashira, Akinori; Morita, Masaru; Kakeji, Yoshihiro; Maehara, Yoshihiko.

In: Gan to kagaku ryoho. Cancer & chemotherapy, Vol. 33 Suppl 1, 01.01.2006, p. 87-90.

Research output: Contribution to journalReview article

Takahashi, I, Oki, E, Egashira, A, Morita, M, Kakeji, Y & Maehara, Y 2006, 'Combination chemotherapy of S-1 plus biweekly docetaxel for advanced and recurrent gastric cancer', Gan to kagaku ryoho. Cancer & chemotherapy, vol. 33 Suppl 1, pp. 87-90.
Takahashi, Ikuo ; Oki, Eiji ; Egashira, Akinori ; Morita, Masaru ; Kakeji, Yoshihiro ; Maehara, Yoshihiko. / Combination chemotherapy of S-1 plus biweekly docetaxel for advanced and recurrent gastric cancer. In: Gan to kagaku ryoho. Cancer & chemotherapy. 2006 ; Vol. 33 Suppl 1. pp. 87-90.
@article{b835e5af6b0049dbbf4e562d54c1a35b,
title = "Combination chemotherapy of S-1 plus biweekly docetaxel for advanced and recurrent gastric cancer",
abstract = "The S-1 +biweekly docetaxel (DOC) combination therapy was evaluated for advanced or recurrent gastric cancer patients. This combination therapy was evaluated in vitro using the nude rat-gastric cancer xenograft system. S-1 alone or DOC alone showed antitumor activity, and the antitumor activity was synergistic when two drugs were combined. In clinical settings, the schedule was S-1 80 mg/m2 (day 1-14, orally) and DOC (day 1 and day 15, intravenously) followed by a 2-week rest. In phase I study, the dose of DOC was evaluated, and a recommended dose for phase II was determined as 35 mg/m2. The entry for phase II study was completed, and the preliminary results of 33 patients showed the response rate of 21.2{\%}. The incidence of more than grade 3 adverse effects was 29{\%}(neutropenia, leukocytopenia, anorexia and mucositis). The S-1 +biweekly DOC combination therapy can be a candidate for outpatient chemotherapy for advanced or recurrent gastric cancer.",
author = "Ikuo Takahashi and Eiji Oki and Akinori Egashira and Masaru Morita and Yoshihiro Kakeji and Yoshihiko Maehara",
year = "2006",
month = "1",
day = "1",
language = "English",
volume = "33 Suppl 1",
pages = "87--90",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",

}

TY - JOUR

T1 - Combination chemotherapy of S-1 plus biweekly docetaxel for advanced and recurrent gastric cancer

AU - Takahashi, Ikuo

AU - Oki, Eiji

AU - Egashira, Akinori

AU - Morita, Masaru

AU - Kakeji, Yoshihiro

AU - Maehara, Yoshihiko

PY - 2006/1/1

Y1 - 2006/1/1

N2 - The S-1 +biweekly docetaxel (DOC) combination therapy was evaluated for advanced or recurrent gastric cancer patients. This combination therapy was evaluated in vitro using the nude rat-gastric cancer xenograft system. S-1 alone or DOC alone showed antitumor activity, and the antitumor activity was synergistic when two drugs were combined. In clinical settings, the schedule was S-1 80 mg/m2 (day 1-14, orally) and DOC (day 1 and day 15, intravenously) followed by a 2-week rest. In phase I study, the dose of DOC was evaluated, and a recommended dose for phase II was determined as 35 mg/m2. The entry for phase II study was completed, and the preliminary results of 33 patients showed the response rate of 21.2%. The incidence of more than grade 3 adverse effects was 29%(neutropenia, leukocytopenia, anorexia and mucositis). The S-1 +biweekly DOC combination therapy can be a candidate for outpatient chemotherapy for advanced or recurrent gastric cancer.

AB - The S-1 +biweekly docetaxel (DOC) combination therapy was evaluated for advanced or recurrent gastric cancer patients. This combination therapy was evaluated in vitro using the nude rat-gastric cancer xenograft system. S-1 alone or DOC alone showed antitumor activity, and the antitumor activity was synergistic when two drugs were combined. In clinical settings, the schedule was S-1 80 mg/m2 (day 1-14, orally) and DOC (day 1 and day 15, intravenously) followed by a 2-week rest. In phase I study, the dose of DOC was evaluated, and a recommended dose for phase II was determined as 35 mg/m2. The entry for phase II study was completed, and the preliminary results of 33 patients showed the response rate of 21.2%. The incidence of more than grade 3 adverse effects was 29%(neutropenia, leukocytopenia, anorexia and mucositis). The S-1 +biweekly DOC combination therapy can be a candidate for outpatient chemotherapy for advanced or recurrent gastric cancer.

UR - http://www.scopus.com/inward/record.url?scp=33747389384&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747389384&partnerID=8YFLogxK

M3 - Review article

C2 - 16897979

AN - SCOPUS:33747389384

VL - 33 Suppl 1

SP - 87

EP - 90

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

ER -